Pharmacology & ToxicologybioRxivPreprint
Development of a Stable Lyophilized Formulation of a Quadrivalent Frame-Shift Peptide Vaccine for Cancer Prevention in Lynch Syndrome
Shanker L. Gupta, Bijay Misra, Indu Javeri…·Robert H. Shoemaker
The paper develops a stable lyophilized formulation for a quadrivalent frame-shift peptide vaccine targeting Lynch syndrome-associated cancers, showing stability for 18 months at ambient temperatures.
DOI 10.1101/2025.08.14.670419